A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)
Status:
Completed
Trial end date:
2011-05-12
Target enrollment:
Participant gender:
Summary
There was no well accepted standard of care for participants who failed or were intolerant to
any of the currently approved therapies for myelodysplastic syndromes (MDS). In this study,
participants were initially assigned to receive 55 or 35 milligrams (mg) of oral clofarabine
daily for 5 days. After safety review of the first participants enrolled, the dose was
reduced to 25 milligrams per day (mg/day) for up to 8 cycles as long as the participants
continued to benefit and in the absence of progressive disease.